Electrons spiral with a purpose: A new platform decodes their selective spin
By combining the principles of physics, chemistry, and biology, scientists have crafted a special programmable platform to explore one of the most puzzling quantum mysteries of our time: why electrons seem to choose sides when passing through certain twisted molecules.
This behavior, known as the chiral-induced spin selectivity (CISS) effect, has baffled researchers for over two decades. It shows up in biological processes like photosynthesis and cellular respiration, yet no one fully understands how or why it happens.
Now, researchers from the University of Pittsburgh have engineered an artificial, controllable system that can mimic the conditions under which this strange effect occurs. Their approach could reshape how we study quantum transport and might also help us design new materials for electronics, energy, and even medicine.
"The beauty of our approach is not that it mimics chemistry or biology exactly, but that it allows us to isolate and study individual processes that are relevant in chiral quantum transport," said François Damanet, a physicist and one of the members of the research team.
Back in the late 1990s, scientists Ron Naaman and David Waldeck made a surprising discovery. When electrons pass through films of chiral (twisted) molecules, how easily they can move is decided by their spin, which is a quantum property. Instead of a small noticeable effect, they saw spin-dependent changes as high as 20 percent, a result that stunned the scientific community.
Since then, the CISS effect has popped up in various biological systems, yet researchers haven't been able to pin down the exact mechanism behind it. This is because real biological molecules are complex. They're soft, flexible, constantly moving, and surrounded by water, all of which makes it nearly impossible to isolate the role of chirality alone.
That's where the new platform comes in. The researchers did not try to recreate biology. Instead, they built a clean, programmable playground for electrons. Using a technique developed in 2008, they worked with a special material made from layers of lanthanum aluminate (LaAlO3) and strontium titanate (SrTiO3).
By using a fine-tipped microscopic pen, they could draw paths where electrons can travel. To make those paths chiral, they introduced a clever twist: the probe not only moved in a wavy, serpentine pattern across the surface, but its voltage was also modulated up and down in sync. This combination created spiral-like channels that broke mirror symmetry, the key ingredient of chirality.
These artificial chiral waveguides weren't just pretty shapes. When electrons flowed through them, surprising quantum effects emerged. The team saw unusual conductance patterns and even observed electrons pairing up in ways that shouldn't be possible under strong magnetic fields.
Theoretical models suggested that the spiral geometry created a kind of engineered spin-orbit coupling, which locked the electrons' spin to their direction of motion, just like some theories had proposed for the CISS effect in molecules.
What makes this platform so powerful is that it's fully programmable. Researchers can change the shape, size, and strength of the chiral patterns, erase them, and write new ones, all on the same device. "We can systematically vary parameters like the pitch, amplitude, and coupling strength of chiral modulations—something impossible with fixed structures," Damanet said.
This new platform doesn't try to copy molecules atom-for-atom. Instead, it gives scientists something they've never had before: precise control. In biological systems, everything is messy—molecules wiggle, environments shift, and vibrations interfere with measurements.
However, on this programmable platform, each variable can be changed independently, allowing researchers to test exactly how chirality affects quantum transport. This could help settle long-standing debates about whether spin-orbit interactions, molecular vibrations, or other mechanisms drive the CISS effect.
While the system operates at ultra-cold temperatures and uses inorganic materials, it sets the stage for future hybrid setups that could combine these solid-state tools with real molecules.
The team is already exploring ways to pair their platform with organic materials or carbon nanotubes, and even to run experiments at higher temperatures. The goal isn't to replace biological studies, but to work alongside them, much like how wind tunnels help engineers test aircraft designs before real-world flights.
If successful, this approach could help scientists not only solve the CISS puzzle but also understand other complex quantum systems. It could inspire new materials for spintronics, where electron spin is used in computing, or guide the design of efficient catalysts and bio-inspired energy devices.
The study is published in the journal Science Advances.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
PORTICO-2 designed to validate vafidemstat's efficacy in reducing aggression in BPD patients Primary endpoint: STAXI-2 Trait Anger (patient-reported) Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) (clinician-rated) Additional secondary endpoints will assess global clinical improvement Protocol finalized following FDA guidance and input from leading US psychiatry experts Upcoming KOL webinar to discuss trial design and the urgent medical need in BPD MADRID and CAMBRIDGE, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol for its Phase III PORTICO-2 trial to the U.S. Food and Drug Administration (FDA) to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD). The PORTICO-2 trial builds upon the encouraging results observed in the previous PORTICO Phase IIb study, where vafidemstat demonstrated significant and clinically meaningful reductions in secondary endpoints measuring aggression and overall BPD improvement. Aggression is a key symptom domain in BPD that currently represents a major unmet medical need and will be the primary endpoint in PORTICO-2. Vafidemstat, an orally active LSD1 inhibitor with a novel epigenetic mechanism of action, has shown a favorable safety and tolerability profile across multiple clinical studies. "The submission of PORTICO-2 to the FDA marks a major step forward for Oryzon and for the field of neuropsychiatry of personality disorders," said Carlos Buesa, Chief Executive Officer of Oryzon. "Borderline Personality Disorder is a highly disabling condition with no approved pharmacological treatments. With its novel epigenetic mechanism, vafidemstat has the potential to become the first targeted therapy specifically addressing aggression and overall improvement in BPD, offering real hope for patients and clinicians confronting this serious disorder. Vafidemstat has also the potential to manage aggression in other neurodevelopmental and neurodegenerative disorders, and we are planning to explore it in a new trial in aggression in ASD." The Phase III protocol was developed through multiple interactions and constructive exchanges with the FDA. Its final design was further refined with the scientific contribution of internationally recognized psychiatric experts, including Dr. Alan Schatzberg (Stanford University), Dr. Eric Hollander (Albert Einstein Medical School), Dr. Emil Coccaro (Ohio State University Wexner Medical Center), and Dr. Sarah Fineberg (Yale University). PORTICO-2 will employ two clinical outcome measures for aggression: the STAXI-2 Trait Anger scale (patient-reported) as the primary endpoint, and the Overt Aggression Scale-Modified (OAS-M) (clinician-rated) as key secondary endpoint. Additional secondary endpoints will evaluate broader clinical improvements in BPD symptomatology and quality of life. A dedicated Key Opinion Leader (KOL) webinar is planned in the coming weeks to discuss the PORTICO-2 study design, the substantial unmet medical need in BPD, and the role of aggression as a clinical target. Details will be announced in a further communication. PORTICO-2 will be a randomized, double-blind, placebo-controlled, multi-center study to assess both the efficacy and safety of vafidemstat in BPD patients, and aims to randomize 350 patients. BPD affects approximately 1-2% of the general population and is characterized by pervasive emotional instability, impulsivity, interpersonal dysfunction, unstable self-image and frequent episodes of aggression and self-harm. More than 75% of BPD patients attempt suicide, and the rate of completed suicide has been estimated to be approximately 10%, 50-times higher than in the general population. Currently, there are no FDA-approved medications specifically indicated for the treatment of BPD, underscoring the urgent need for novel therapeutic approaches. Additional exploratory data from earlier Phase IIa studies suggest that vafidemstat may also reduce aggression in other patient populations, including Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), and Alzheimer's Disease (AD). The company is planning to explore this further in a new trial in aggression in ASD to be conducted within the activities of the Med4Cure IPCEI-EU Grant. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate, ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit About Vafidemstat Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer's disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong, and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed two Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders (REIMAGINE, see Ferrer et al, Psychiatry & Clin Neurosci, 2025, and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive clinical results reported in both. Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL trial in patients with Mild to Moderate AD, where a significant reduction of the inflammatory biomarker YKL40 was observed after 6 and 12 months of treatment, and the pilot, small-scale SATEEN trial in Relapse-Remitting and Secondary Progressive MS, where anti-inflammatory activity was also observed. Vafidemstat has also been tested in a Phase II in severe Covid-19 patients (ESCAPE) assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection, where it showed significant anti-inflammatory effects in severe Covid-19 patients. Vafidemstat is currently advancing as a Phase III-ready asset in Borderline Personality disorder (BPD) following completion of the global, randomized, double blind Phase IIb PORTICO trial (final data presented at ECNP-2024). Following receipt of the minutes from the End-of-Phase II meeting with the FDA to discuss PORTICO's results, the company announced plans to move forward with a Phase III PORTICO-2 trial in agitation/aggression in BPD (PhIII protocol submitted to FDA). Vafidemstat is also being investigated in a double-blind, randomized, placebo-controlled Phase IIb trial in negative symptoms of schizophrenia (EVOLUTION trial, recruitment ongoing). The company is also deploying a CNS precision medicine approach with vafidemstat in genetically defined patient subpopulations of certain CNS disorders, as well as in neurodevelopmental syndromes, and is evaluating the feasibility of conducting clinical trials in autistic conditions like Fragile X syndrome and Phelan-McDermid syndrome. FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.. Spain Oryzon IR & Media, Europe & US Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid Atrevia Chief BD Officer LifeSci Advisors, LLC +34 91 564 07 25 +34 673 33 97 65 +34 93 515 1313 +41 78 680 05 38 pcobo@ mcordera@ etorrell@ svonderweid@
Medscape
an hour ago
- Medscape
Which Second-Line Therapy Is Better for Right-Sided CRC?
TOPLINE: Continuing anti-VEGF therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with right-sided, RAS/RAF wild-type metastatic colorectal cancer (CRC) compared to patients who received anti-epidermal growth factor receptor (EGFR) therapy plus chemotherapy. METHODOLOGY: Despite limited evidence, guidelines recommend anti-EGFR therapy plus chemotherapy in the second line for patients with RAS/RAF wild-type, right-sided tumors who did not previously receive anti-EGFR therapy. To assess whether this is the best option, the current study compared the effectiveness of continuing chemotherapy plus anti-VEGF in the second-line or using anti-EGFR plus chemotherapy. Researchers used electronic health record data from 280 community oncology clinics in the US. The analysis included 444 patients (median age, 65 years) with RAS/RAF wild-type, right-sided metastatic CRC who received first-line chemotherapy plus anti-VEGF therapy, followed by second-line anti-VEGF therapy (n = 269) or anti-EGFR therapy (n = 175) with chemotherapy. Researchers then compared overall survival in these two groups. TAKEAWAY: Compared with the anti-VEGF therapy group, the anti-EGFR therapy group demonstrated a nonsignificant increased risk for death (hazard ratio [HR], 1.24; P = .10). The median overall survival was 15.3 months with anti-VEGF therapy vs 12.0 months with anti-EGFR therapy. The findings were consistent with first-line trial results, showing nonsignificant worse overall survival with anti-EGFR vs anti-VEGF therapy in right-sided tumors (HR, 1.09). IN PRACTICE: Among patients with RAS/RAF wild-type, right-sided metastatic CRC who received first-line chemotherapy plus anti-VEGF therapy, these findings 'provide some evidence for continuing anti-VEGF therapy in the second line, although the result was not statistically significant,' the authors wrote. SOURCE: This study, led by Nishwant Swami, MD, MPH, Hospital of the University of Pennsylvania, Philadelphia, was published online in JAMA Network Open. LIMITATIONS: This study was limited by possible unmeasured confounding factors and had limited statistical power due to the relatively small proportion of mCRC cases that were right-sided and RAS/RAF wild-type. DISCLOSURES: No funding information was provided for this study. Several authors reported receiving grants and personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
US company reaches critical turning point in journey to build nearly limitless energy device: 'Provides a sound foundation'
Type One Energy has successfully passed the first formal design review for its "Infinity Two" stellarator fusion reactor power plant that aims to deliver 350 megawatts of electricity to the grid by the mid-2030s. The U.S.-based company has been developing the technology for a potential project with the Tennessee Valley Authority, which provides power to a seven-state region in the Southeast. The progress on the Infinity Two reactor design and the partnership with TVA have been turning heads in the global energy industry, according to a report by Interesting Engineering. In a press release, the company shared that "several prominent energy utilities and industrial companies have expressed an interest in Infinity Two and participation in Type One Energy's deployment of its first-generation fusion power plant technology." Stellarator fusion reactors such as the Infinity Two use strong electromagnets to create a twisting magnetic field to confine plasma and create the right conditions for fusion. These types of reactors require less injected power and offer greater design flexibility, but they are also incredibly complex to engineer. Researchers at the Princeton Plasma Physics Laboratory even created customized code called QUADCOIL to help optimize and accelerate the design process for these types of reactors. According to Interesting Engineering, this is the first time that a fusion power plant with such a significant output goal has passed an independent technical review, which could be a turning point in the race to commercialize the sector. Fusion holds the promise of nearly limitless carbon-free energy, which could serve as a complement to other sustainable energy sources such as solar and wind. While it's still a work in progress, there have been many advances in the field. The Infinity Two's design review board includes Type One Energy's chief technology officer, Thomas Sunn Pedersen, as well as prominent outside experts such as George H. "Hutch" Neilson from the Princeton Plasma Physics Laboratory and Paolo Ferroni from Westinghouse Electric Company, according to the report. Should the government be paying us to upgrade our homes? Definitely Depends on how much it costs Depends on what it's for No way Click your choice to see results and speak your mind. The project received high praise from Neilson, who said: "It is the first serious fusion power plant design that I've seen. The work they've done to date provides a sound foundation for continued design development of what could be the first system to produce net electricity from fusion." The record-breaking Wendelstein 7-X fusion project at the Max Planck Institute for Plasma Physics in Germany has already proved the potential for stable steady-state operation at a large scale for stellarator designs, paving the way for projects such as the Infinity Two. Soon, we may be able to stop relying on dirty fuels from the oil and gas industry and instead enjoy the clean, sustainable energy output from fusion reactors without polluting the environment. Fusion reactors are incredibly efficient. With just over 130 pounds of deuterium and tritium, they can create the same amount of energy as 275,000 tons of petrol. "The energy industry needs more reliable, clean, power generation technology that can meet the rapidly increasing demand for electricity and we are delivering a commercially compelling solution," said Christofer Mowry, CEO of Type One Energy. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
